bucindolol

bucindolol

An investigational, nonselective beta-blocker with vasodilating properties that reached phase-III (BEST) trials, but was dropped from development thereafter.

bucindolol

Bextra Cardiology An investigational nonselective beta-blocker with vasodilating properties; removed from marketplace
Mentioned in ?
References in periodicals archive ?
Cardiosseletivos Nao seletivos Drogas com atividade al antagonista adicional Acebutolol * Alprenolol * Bucindolol Atenolol Carteolol * Carvedilol Betaxolol Nadolol Labetalol Bevantolol Oxprenolol * Bisoprolol Penbutolol * Celiprolol Pindolol * Esmolol Propranolol Metoprolol Sotalol Practolol * Timolol Quadro 4: Criterios usados na selecao e forma de obtencao dos dados.
However, carriers of this genotype have a greater improvement of left ventricular function during treatment with metoprolol but not with bucindolol [45].
According to the company, the proceeds may be used for working capital, clinical development of bucindolol, including GENETIC-AF, the ongoing Phase 2B/3 trial for atrial fibrillation, to fund its operations, at the projected cost structure, through the end of 2017 or may use the capital faster or slower than currently anticipated.
They also compared atenolol, bisoprolol, bucindolol, carvedilol, metoprolol, and nebivolol with each other and found no significant difference in risk of death, sudden cardiac death, death resulting from pump failure, or tolerability.
A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure (BEST)' calismasinda genel olarak busindolol tedavisinin sistolik kalp yetersizligi hastalarinda yararli olmadigi gosterilmistir (40).
patent on methods of treating heart failure patients with bucindolol hydrochlorid--tradenamed Gencaro--based on genetic testing.
Las investigaciones concluyen que, a diferencia de los demas bloqueantes beta, el bucindolol es un farmaco con dos propiedades farmacogeneticas unicas: los pacientes con falla cardiaca portadores del genotipo Arg389Arg del gen ADRB1 o del genotipo Ins/Ins del gen ADRA2C son los beneficiados por el medicamento, con el maximo beneficio conseguido en quienes portan ambos genotipos.
Researchers reported that heart-failure patients with a certain genetic profile responded well to bucindolol, a beta blocker that had fallen out of favor because it wasn't very effective in the average patient.
Three studies looked at propranolol, one study at sotalol, one study at atenolol, one study at bucindolol, and one study at atenolol, metoprolol, and pindolol.
37) For example, carve-dilol and bucindolol are nonselective beta blockers with intrinsic vasodilator activity.
In a DNA subanalysis of the Beta-Blocker Evaluation of Survival Trial (BEST), the [beta]-blocker bucindolol improved survival and decreased hospitalizations in heart failure (HF) patients with the adrenergic receptor variant known as Arg 389, compared with placebo.